Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13037837 | 0.87 | CRHR1 (0.41) | CRHR1TDP1 | |
| SCHEMBL6092339 | 0.80 | CRHR1 (0.57) | CRHR1TDP1 | |
| SCHEMBL1762903 | 0.78 | CRHR1 (0.46) | CRHR1TDP1 | |
| SCHEMBL3615202 | 0.76 | CDK4 (0.42) | CRHR1 | |
| SCHEMBL12535355 | 0.75 | CRHR1 (0.55) | CRHR1TDP1 | |
| SCHEMBL6215835 | 0.74 | CRHR1 (0.41) | CRHR1TDP1 | |
| SCHEMBL3618790 | 0.72 | CRHR1 (0.51) | CRHR1TDP1 | |
| SCHEMBL6219189 | 0.72 | CRHR1 (0.38) | CRHR1TDP1 | |
| SCHEMBL6220396 | 0.69 | CRHR1 (0.36) | CRHR1TDP1 | |
| SCHEMBL6216339 | 0.68 | CRHR1 (0.33) | CRHR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280053-A1 | CyclopropylmethYl-[7-(5,7-dimethyl-benzo[1,2,5]thiodiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-4-propyl-amine as a CRF Antagonist | NOVARTIS AG | 2010-11-04 | — | — | US | disclosed |
| US-20070142407-A1 | Benzo (1,2,5) thiadiazole als crf-antagonisten | NOVARTIS AG (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1594506-A1 | BENZO (1,2,5) THIADIAZOLE ALS CRF-ANTAGONISTEN | Novartis AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069257-A1 | BENZO (1,2,5) THIADIAZOLE ALS CRF-ANTAGONISTEN | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142407-A1 | Benzo (1,2,5) thiadiazole als crf-antagonisten | SMN1; SMN2, GRIK5, GRIN1 | CRHR1 9/4885TDP1 696/4885 |
| US-20100280053-A1 | CyclopropylmethYl-[7-(5,7-dimethyl-benzo[1,2,5]thiodiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-4-propyl-amine as a CRF Antagonist | CRH, CRHR2, MC2R | CRHR1 4/4885TDP1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.